Is ARIA a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

2,549 people get ARIA articles and Market Currents by email alert.

Get email alerts on ARIA »

HEADLINES:

ARIAD to Present at the Deutsche Bank 38th Annual Healthcare Conference

Business Wire (Thu, 7:35AM)
Ariad's Cancer Drug Iclusig Extends The Gleevec Magic
Peter Geschek • Wed, May 22 • 4 Comments
Ariad Pharmaceuticals' CEO Presents at UBS Global Healthcare Conference (Transcript)
Mon, May 20
ARIAD Announces Data Presentations and Webcast of Investor Briefing at the 2013 ASCO Annual Meeting

Business Wire (May 15, 2013)
ARIAD Pharmaceuticals' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)
Tue, May 14
2 Biotech Companies With Strong Product Launches To Monitor
The Swiss Trader • Tue, May 14 • 3 Comments
ARIAD to Present at UBS Global Healthcare Conference

Business Wire (May 13, 2013)
Recent Noteworthy Institutional 5% Ownership Filings In Healthcare Sector
GuruFundPicks • Thu, May 9 • 5 Comments
Ariad Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
Tue, May 7
ARIAD Reports First Quarter 2013 Financial Results and Development Progress

Business Wire (May 7, 2013)
ARIAD to Present at Bank of America Merrill Lynch Healthcare Conference

Business Wire (May 6, 2013)
ARIAD to Host Conference Call and Webcast Discussion of First Quarter 2013 Financial Results on May 7, 2013

Business Wire (Apr 23, 2013)
AVEO Poised To Move Higher Before FDA Adcomm Catalyst, Obamacare And Platform Potential
Scott Matusow • Tue, Apr 16 • 43 Comments
2 Oncology Biotechs For The Future
Bio Matt • Sun, Apr 14 • 10 Comments
ARIAD Presents New Preclinical Data Showing AP26113 Inhibits Clinically Relevant Mutants of ALK and ROS1

Business Wire (Apr 10, 2013)
ARIAD Presents New Preclinical Data Showing Ponatinib Overcomes Resistant Mutations in KIT, an Oncogenic Driver of Gastrointestinal Stromal Tumors

Business Wire (Apr 9, 2013)
ARIAD Presents New Preclinical Data Showing Ponatinib is a Potent Inhibitor of RET and FGFR, Two Oncogenic Drivers of Non-Small Cell Lung Cancer

Business Wire (Apr 8, 2013)
Can Bristol-Myers Squibb Compete In Immuno-Oncology?
Bio Matt • Mon, Apr 8 • 5 Comments
A Quick Response To Ariad's Conference Call
Prohost Biotech • Fri, Apr 5 • 20 Comments
Ariad Pharmaceuticals' CEO Hosts Investor Conference (Transcript)
Thu, Apr 4 • 1 Comment

To learn more about Seeking Alpha Pro, click here.

Ariad's Cancer Drug Iclusig Extends The Gleevec Magic
Peter Geschek • Wed, May 22 • 4 Comments
A Quick Response To Ariad's Conference Call
Prohost Biotech • Fri, Apr 5 • 20 Comments
Why Are Investors Excited About Ariad?
C.R. Jackson • Thu, Feb 28 • 3 Comments
Ariad: Shares Overvalued On Fundamentals
Poonam A. Arora • Tue, Feb 5 • 32 Comments
Ariad Sees Heavy Drop Following Spontaneous FDA Approval
Brian L. Wilson • Wed, Dec 19, 2012 • 4 Comments
Ariad: Iclusig's Approval Deserves Honoring The Developer, Not Bashing Its Stock
Prohost Biotech • Tue, Dec 18, 2012 • 3 Comments
Ariad's Wonder Drug For Leukemia Patients
Peter Geschek • Mon, Dec 17, 2012
Ariad Passes Its 12-Month Check-Up
EP Vantage • Mon, Dec 10, 2012
Ariad: A Very Interesting Biotech With An Even More Promising Pipeline
Matt Schilling • Tue, Nov 13, 2012 • 3 Comments
Ariad Pharmaceuticals' AP26113: Strong Data For ALK+ Lung Cancer
Longwood Bulls • Tue, Oct 2, 2012 • 3 Comments
Ariad Pharmaceuticals: Ponatinib Approval Anticipated In Second-Line CML
LifeSci Advisors • Mon, Oct 1, 2012 • 1 Comment
Ariad Pharmaceuticals Gearing Up For Ponatinib's Approval
Longwood Bulls • Wed, Aug 29, 2012 • 10 Comments
Investors Already Expect A Lot From Ariad Pharmaceuticals
Stephen Simpson • Mon, Apr 9, 2012 • 3 Comments
Ariad's mTOR And The FDA Committee
Prohost Biotech • Wed, Mar 21, 2012
Ariad Pharma Sees Huge Setback In Its Sarcoma Maintenance Drug Ridaforolimus
Scott Matusow • Wed, Mar 21, 2012 • 70 Comments
Ariad Prepares For FDA Committee
Prohost Biotech • Tue, Mar 20, 2012 • 4 Comments
Aria And Talon: Is An Advisory Panel Meeting A Profitable Trading Catalyst?
BinaryLeverage • Sun, Mar 4, 2012 • 11 Comments
Ariad Pharmaceuticals Is Worth Your Long-Term Investment
John Mylant • Thu, Feb 23, 2012 • 4 Comments
Ariad: This Bio-Pharma May Deliver Big Returns
Scott Matusow • Wed, Jan 11, 2012 • 13 Comments
Ariad's ALK Inhibitor Could Be Huge Step Forward in Lung Cancer Treatment
Prohost Biotech • Sun, Jun 19, 2011 • 2 Comments

2 Biotech Companies With Strong Product Launches To Monitor
The Swiss Trader • Tue, May 14 • 3 Comments
Recent Noteworthy Institutional 5% Ownership Filings In Healthcare Sector
GuruFundPicks • Thu, May 9 • 5 Comments
AVEO Poised To Move Higher Before FDA Adcomm Catalyst, Obamacare And Platform Potential
Scott Matusow • Tue, Apr 16 • 43 Comments
2 Oncology Biotechs For The Future
Bio Matt • Sun, Apr 14 • 10 Comments
Can Bristol-Myers Squibb Compete In Immuno-Oncology?
Bio Matt • Mon, Apr 8 • 5 Comments
Cramer's Mad Money - The Dow Confounds The Bears (2/27/13)
SA Editor Miriam Metzinger • Thu, Feb 28
Special Protocol Assessments: The Case Studies
PropThink • Fri, Feb 22 • 1 Comment
Biotech Mid Caps, Dangerous Slippery Slopes
Ryan's View • Tue, Feb 12 • 5 Comments
Which Companies Are In Michael King's Oncology Wheelhouse?
Life Sciences Report • Sat, Jan 12 • 2 Comments
ArQule: A Strong Speculation BioPharma Poised For A Quick Move Up On Near Term Catalyst
Scott Matusow • Wed, Dec 19, 2012 • 2 Comments
Weekly Biotech Recap: Anticipation, Divergence
Brian L. Wilson • Mon, Dec 17, 2012 • 6 Comments
Synta Pharma: Poised For A Breakout With 4 Near-Term Catalysts
Scott Matusow • Thu, Dec 13, 2012 • 5 Comments
Mid-Week Biopharma Catalyst Trades To Consider
Scott Matusow • Thu, Dec 13, 2012 • 7 Comments
Tuesday's Small-Cap Biopharma Catalyst Trade List
Scott Matusow • Tue, Dec 11, 2012 • 19 Comments
Small-Cap Biotechs That Could Make Big Moves This Week
Scott Matusow • Mon, Dec 10, 2012 • 36 Comments
Pharma Stock Movements After FDA ADCOM And EU EMA Decisions This Week
Scott Matusow • Fri, Oct 19, 2012 • 2 Comments
5 Bio-Pharmas On The Rise With Potential Groundbreaking And Lifesaving Treatments
Scott Matusow • Tue, Oct 9, 2012 • 14 Comments
Winners Of ESMO 2012
Ohad Hammer • Mon, Oct 8, 2012 • 6 Comments
Cramer's Mad Money - Warnaco Should Say 'Goodbye' To Calvin Klein (9/18/12)
SA Editor Miriam Metzinger • Wed, Sep 19, 2012 • 1 Comment
5 Pharmaceutical Companies With EMA Catalysts During The Next 3 - 12 Months - Part II
Markus Aarnio • Sun, Sep 2, 2012 • 2 Comments

Ariad Pharmaceuticals' CEO Presents at UBS Global Healthcare Conference (Transcript)
Mon, May 20
ARIAD Pharmaceuticals' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)
Tue, May 14
Ariad Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
Tue, May 7
Ariad Pharmaceuticals' CEO Hosts Investor Conference (Transcript)
Thu, Apr 4 • 1 Comment
Ariad Pharmaceuticals' CEO Presents at Barclays Global Healthcare Conference (Transcript)
Wed, Mar 13
Ariad Pharmaceuticals Management Discusses Q4 2012 Results - Earnings Call Transcript
Mon, Feb 25
ARIAD Pharmaceuticals' CEO Presents at Lazard Capital Markets Healthcare Conference (Transcript)
Thu, Nov 15, 2012
Ariad Pharmaceuticals Management Discusses Q3 2012 Results - Earnings Call Transcript
Wed, Nov 7, 2012
ARIAD Pharmaceuticals' CEO Hosts ARIAD ESMO Investor Conference Call (Transcript)
Mon, Oct 1, 2012
Ariad Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript
Thu, Aug 2, 2012
ARIAD Pharmaceuticals CEO Discusses Q3 2010 - Earnings Call Transcript
Wed, Nov 10, 2010
ARIAD Pharmaceuticals, Inc. Q2 2010 Earnings Call Transcript
Wed, Aug 4, 2010
ARIAD Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript
Mon, May 10, 2010
ARIAD Pharmaceuticals Inc. Q4 2008 Earnings Call Transcript
Thu, Feb 12, 2009
ARIAD Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
Thu, Nov 6, 2008
ARIAD Pharmaceuticals, Inc. Q2 2008 Earnings Call Transcript
Tue, Sep 2, 2008
Ariad Pharmaceuticals Inc. Q1 2008 Earnings Call Transcript
Mon, May 26, 2008

ARIAD to Present at the Deutsche Bank 38th Annual Healthcare Conference

Business Wire (Thu, 7:35AM)
ARIAD Announces Data Presentations and Webcast of Investor Briefing at the 2013 ASCO Annual Meeting

Business Wire (May 15, 2013)
ARIAD to Present at UBS Global Healthcare Conference

Business Wire (May 13, 2013)
ARIAD Reports First Quarter 2013 Financial Results and Development Progress

Business Wire (May 7, 2013)
ARIAD to Present at Bank of America Merrill Lynch Healthcare Conference

Business Wire (May 6, 2013)
ARIAD to Host Conference Call and Webcast Discussion of First Quarter 2013 Financial Results on May 7, 2013

Business Wire (Apr 23, 2013)
ARIAD Presents New Preclinical Data Showing AP26113 Inhibits Clinically Relevant Mutants of ALK and ROS1

Business Wire (Apr 10, 2013)
ARIAD Presents New Preclinical Data Showing Ponatinib Overcomes Resistant Mutations in KIT, an Oncogenic Driver of Gastrointestinal Stromal Tumors

Business Wire (Apr 9, 2013)
ARIAD Presents New Preclinical Data Showing Ponatinib is a Potent Inhibitor of RET and FGFR, Two Oncogenic Drivers of Non-Small Cell Lung Cancer

Business Wire (Apr 8, 2013)
ARIAD Provides Update on Important Progress Being Made in R&D and Commercial Initiatives

Business Wire (Apr 4, 2013)
CORRECTING and REPLACING ARIAD to Host Investor Conference Call Tomorrow, April 4th at 8:00 A.M. ET

Business Wire (Apr 3, 2013)
ARIAD Announces Support of Patients with Resistant or Intolerant CML Through Its Donation to Chronic Disease Fund

Business Wire (Apr 2, 2013)
3 Under-the-Radar Tech Stocks: Top Portfolio Manager

at CNBC.com (Apr 1, 2013)
ARIAD Announces That Iclusig™ (Ponatinib) Receives Positive CHMP Opinion for Approval in the European Union

Business Wire (Mar 22, 2013)
ARIAD Announces Presentations of Preclinical Data at American Association for Cancer Research Annual Meeting

Business Wire (Mar 20, 2013)
ARIAD to Present at Barclays Global Healthcare Conference

Business Wire (Mar 6, 2013)
ARIAD to Present at the Cowen and Company 33rd Annual Health Care Conference

Business Wire (Feb 28, 2013)
ARIAD Reports 2012 Financial Results and Outlines Key Objectives for 2013

Business Wire (Feb 25, 2013)
ARIAD Announces Appointment of European General Manager and Other Key Members of Leadership Team

Business Wire (Feb 21, 2013)
ARIAD To Present at The RBC Capital Markets Healthcare Conference

Business Wire (Feb 19, 2013)

ARIA vs. ETF Alternatives

Company Description

ARIAD’s vision is to transform the lives of cancer patients with breakthrough medicines. Our mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need – aggressive cancers where current therapies are... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 16, 1:29 PM Ariad's (ARIA -4.5%) slides on reports that a growing number of tools are allowing many cancer patients to skip chemotherapy or other cancer treatments. Also, ongoing trials of its experimental cancer drug AP26113 has only clouded the picture regarding its potential. A smaller proportion of patients saw their tumors shrink than shown in a previous release and it's unclear whether 2 patient deaths were caused by the drug or something else. Analysts expect more clarity when ARIA presents more-mature data at June's ASCO cancer meeting. 1 Comment [Healthcare, On the Move]
Tuesday, May 7, 8:16 AM More on Ariad Pharmaceuticals' (ARIA) Q1 report: The fiery debate surrounding Q1 Iclusig sales (estimates were $3.5-6M) is over as ARIA says net sales of the leukemia drug were $6.4M during the period (the company deferred $3.3M based on the sell-through revenue recognition method it uses). Favus Institutional Research sparked a contentious debate last month after it raised side effect-related concerns on Iclusig which was tagged with what some said was an unexpected liver toxicity warning when it was approved in December. Shares +3% premarket. (PR) Comment! [Healthcare, On the Move, Earnings]
Tuesday, May 7, 7:37 AM Ariad Pharm (ARIA): Q1 EPS of -$0.36 in-line. Revenue of $6.46M beats by $1.45M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, May 7, 12:05 AM Notable earnings before Tuesday’s open: ACM, AFAM, AKRX, ALLT, ARCC, ARIA, BCRX, CHTR, CMLP, CNK, CQB, CRZO, CVLT, DFT, DISCA, DTV, DWRE, EMR, ENDP, FE, FOSL, HCN, HFC, HPT, HSIC, KWK, LPX, NRG, NRGY, NVAX, OAK, OMX, PQ, PRGO, RIGL, SHOO, TA, TAP, TDG, TGH, TICC, TRGT, TW, WRES, XEC 2 Comments [Earnings]
Monday, May 6, 5:30 PM Notable earnings before Tuesday's open: ACM, AFAM, AKRX, ALLT, ARCC, ARIA, BCRX, CHTR, CMLP, CNK, CQB, CRZO, CVLT, DFT, DISCA, DTV, DWRE, EMR, ENDP, FE, FOSL, HCN, HFC, HPT, HSIC, KWK, LPX, NRG, NRGY, NVAX, OAK, OMX, PQ, PRGO, RIGL, SHOO, TA, TAP, TDG, TGH, TICC, TRGT, TW, WRES, XEC Comment! [Earnings]
Monday, April 8, 8:07 AM Ariad Pharmaceuticals (ARIA) says preclinical data suggest the company's leukemia drug Iclusig may inhibit two drivers of tumors in medullary thyroid cancer and non-small cell lung cancer. Ariad took a hit last week when a research firm suggested Iclusig's adverse side effects were proving to be more prevalent than anticipated. Comment! [Healthcare]
Thursday, April 4, 9:10 AM Premarket gainers: CBMX +20%. PSDV +13%. NAVB +10%. ALU +9%. ARIA +6%.
Comment! [On the Move]
Thursday, April 4, 8:01 AM Ariad Pharmaceuticals (ARIA +1.4%) says that over 325 U.S. patients are being treated with its Iclusig drug for myeloid leukemia, just 12 weeks after the medicine was launched. Ariad expects EU approval in Q2 for launch in the region in July. The company is also on track to start Phase 2 pivotal trials of its AP26113 (lung cancer, brain mestastases) drug in Q3. (PR) Comment! [Healthcare]
Wednesday, April 3, 1:15 PM Ariad Pharmaceuticals (ARIA -4.8%) is having a rough day after an analyst at Favus Institutional Research said survey data shows the company's leukemia drug Iclusig (Ariad's first product to reach market) may be producing "a much larger-than-expected number of serious side effects" such as pancreatitis, stroke, and non-reversable liver toxicity. When the drug received early approval in December some analysts were surprised to see "liver toxicity" as a possible side effect on the drug's label. 2 Comments [Healthcare, On the Move]
Thursday, March 28, 2:13 PM Ariad Pharmaceuticals (ARIA -0.8%) gets only a tentative nod from Goldman Sachs today, after the company initiated the shares with a Neutral rating, saying the stock is fairly valued at current levels. Goldman notes that since its launching of Iclusig last December, the stock has already appreciated 55%, and trades at a healthy premium to both its cancer peers and the broader S&P 500 index. 2 Comments [Healthcare]
Monday, February 25, 7:39 AM Ariad Pharmaceuticals (ARIA): Q4 EPS of -$0.36 in-line. Revenue of $74K. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, February 25, 12:05 AM Notable earnings before Monday’s open: ARIA, BGC, CTB, CWH, DDD, DNDN, FE, HL, HTZ, KWK, LOW, SFL Comment! [Earnings]
Sunday, February 24, 5:30 PM Notable earnings before Monday’s open: ARIA, BGC, CTB, CWH, DDD, DNDN, FE, HL, HTZ, KWK, LOW, SFL Comment! [Earnings]
Thursday, January 24, 12:54 PM Ariad Pharmaceuticals (ARIA -2.4%) slips today after pricing its 15.3M share offering at $19.60 a share, a 1.3% discount to Wednesday's close. The company's float stands at around 166.3M shares. ARIA plans to use the proceeds for making and marketing its leukemia treatment Iclusig and for developing its other drug candidates. Comment! [Healthcare, On the Move]
Monday, December 17, 2012, 2:44 PM Shares of Ariad Pharmaceutical (ARIA +5.7%) get a boost today as a number of firms come out in defense of the stock following last weeks drubbing. The FDA approved its leukemia treatment Iclusig, but with an unexpected boxed warning. Jefferies says the safety issues are hard to pinpoint directly to the drug and lowers its price target, but reiterates a Buy on the shares. Maxim reiterates a Buy as well, saying the potentially lower penetration due to reduced prescriptions is partially offset by a higher-than-expected selling price. 1 Comment [Healthcare, On the Move]
Friday, December 14, 2012, 2:04 PM Ariad Pharmaceuticals (ARIA -9.5%) drops after the FDA approves Iclusig, its chronic myeloid leukemia treatment, more than three months ahead of the product’s its scheduled release. However, the drug was approved with a boxed warning alerting patients and health care professionals that the drug can cause blood clots and liver toxicity, which was not anticipated. Comment! [Healthcare, On the Move]

TipRanks
$GS analyst Terence Flynn started $ARIA BUY. his average return on Buy ratings is -2.8% below the SP500
Mar 28, 12:22 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ryan Mallory
A Lot of New Additions to the Short Watch-List | $EBAY $ARIA $BBVA at the top of the list http://bit.ly/ZQ0ZCf
Mar 25, 12:23 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Scientist
Boxed warning a total shock for $ARIA. Arterial thrombosis is quite rare but extremely dangerous. 8% is a high number.
12/14/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

sprasad03
When to buy $ARIA ?
12/5/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Joe Springer
Insider's showing their hands: http://bit.ly/TuYnnJ $MNKD $ARIA $VRTX $OREX $FOLD $ZLTQ $ISIS
10/17/12
Reply (4)

• !Report Abuse
View all 4 replies
mark woods: Did you say FOLD had strong insider selling or buying?
10/18/12
• !Report Abuse
Joe Springer: Hey Mark - Buying http://bit.ly/U9xCdG
10/18/12
• !Report Abuse
Add a reply...

140 characters

Ryan Mallory
14 Stocks That Only Go Up & Up http://bit.ly/SJ796L ABT ALGN ARIA BBH BIIB CTBI DHI EQIX HD HOMB MDVN PCYC SHW TCBI
10/8/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

jtank
I'm late to the game, but I'm looking to open a position in ARIA - will it continue to rise?
8/17/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dr. Kris
Looking for low-priced "Blue Chips"? Consider these up-trending, outperforming stocks <$30: $ARIA, $CLGX, $ELLI, $HW, $ITPOF, $LPX, $WIBC.
8/15/12
Reply (4)

• !Report Abuse
View all 4 replies
Dr. Kris: Joe: Absolutely! However, it's starting to look at little toppy. Gains are decreasing and volume is shrinking. Stock needs a catalyst.
8/16/12
• !Report Abuse
Joelitch: Ya, i'm in on an ESPP at 9, can't sell until end of Sept. and believe me, I will be doing asap!
8/16/12
• !Report Abuse
Add a reply...

140 characters

Joe Springer
$VVUS $SPPI $OMPI $ARIA $PSTI $NEPT $IBIO $CRTX $AMGN Got one warning about Bios coming, some that rallied: http://seekingalpha.com/a/gxpr
8/8/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
http://bit.ly/IBl85G Earnings before market open: AOL, ARIA, DF, DTG, FXCM, IHG, KELYA, M, SVNT, TEVA, TM, SODA
5/8/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Joe Springer
Insider's showing their hands: http://bit.ly/TuYnnJ $MNKD $ARIA $VRTX $OREX $FOLD $ZLTQ $ISIS
10/17/12
Reply (4)

• !Report Abuse
View all 4 replies
mark woods: Did you say FOLD had strong insider selling or buying?
10/18/12
• !Report Abuse
Joe Springer: Hey Mark - Buying http://bit.ly/U9xCdG
10/18/12
• !Report Abuse
Add a reply...

140 characters

Dr. Kris
Looking for low-priced "Blue Chips"? Consider these up-trending, outperforming stocks <$30: $ARIA, $CLGX, $ELLI, $HW, $ITPOF, $LPX, $WIBC.
8/15/12
Reply (4)

• !Report Abuse
View all 4 replies
Dr. Kris: Joe: Absolutely! However, it's starting to look at little toppy. Gains are decreasing and volume is shrinking. Stock needs a catalyst.
8/16/12
• !Report Abuse
Joelitch: Ya, i'm in on an ESPP at 9, can't sell until end of Sept. and believe me, I will be doing asap!
8/16/12
• !Report Abuse
Add a reply...

140 characters

flyisu2002
$AAPL to buy $EKDKQ patent porfoio called it yesterday your wlcome very much.. $MDFI $ARIA $JVA $AFFY all set to run
3/15/12
Reply (1)

• !Report Abuse
View all 1 replies
x oil -field: Eastman Kodak Co. (EKDKQ.PK) gaining new interest and highs today. (AAPL)
3/16/12
• !Report Abuse
Add a reply...

140 characters

Ryan Mallory
3/2 Video Watchlist SCEI MELA RSYS MMR GA ATML ARIA SAH UCTT ALNY ACHN BTU REXX INAP ANW CNX ALSK http://www.bit.ly/A4YhPa
3/2/12
Reply (7)

• !Report Abuse
View all 7 replies
Ryan Mallory: sure will
3/6/12
• !Report Abuse
phemale60: has some useful information but I guess they are also trying to push their Biotech Supertrader program. Love their "quote of the day"!
3/6/12
• !Report Abuse
Add a reply...

140 characters

ARIA ARIAD Pharmaceuticals, Inc.

ARIA

ARIAD Pharmaceuticals, Inc.